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Abstract
Background Bariatric surgery is an effective intervention
strategy in obesity, resulting in sustained weight loss and a
reduction of comorbidities. Gastroplication, using the articu-
lating circular endoscopic stapler, was recently introduced as a
transoral bariatric technique. This procedure reduces gastric
volume and induced 34.9 % of excess weight loss in the first
year (Paulus et al. Gastrointest Endosc. 81(2):312–20, 3). The
aim of the present study was to gain insight in the long-term
effects and underlying mechanisms of gastroplication by in-
vestigating differences in the genome-wide gastric and duo-
denal transcriptome before and 1 year after intervention.
Methods Ten morbidly obese patients (BMI 39.8 ± 0.9 kg/m2
(mean ± SEM)) underwent gastroplication. Previous to the
procedure and after 1 year, blood samples were taken, and
mucosal biopsies were collected from the fundus, antrum
and duodenum. Gene expression was measured using
microarray analysis. Plasma adiponectin, HbA1c, IL-1β, IL-
6, IL-7, TNF-α, IFN-γ, MCP-1, IL-8, TGF-1 and CRP levels
were determined.
Results Downregulation of inflammatory genes and gene sets
was observed in the fundus and duodenum 1 year after sur-
gery. Gene expression of ghrelin and its activating enzyme
GOATwere downregulated in the upper gastrointestinal tract.
Patients showed a reduction in plasma HbA1c levels (from
6.17 ± 0.51 to 5.32 ± 0.14 %, p = 0.004) and an increase of
plasma adiponectin (from 16.87 ± 3.67 to 27.67 ± 5.92 μg/ml,
p = 0.002).
Conclusions Individuals undergoing gastroplication
displayed a downregulation of inflammatory tone in the stom-
ach and duodenum, which coincided with improved HbA1c
and adiponectin levels. The reduction of inflammatory tone in
the upper gastrointestinal tract may be a consequence of an
improved metabolic health status or alternatively caused by
the procedure itself.
Keywords Gastroplication . Transcriptome . Gene
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Introduction
Bariatric surgery is the most effective medical option to
achieve sustained weight loss in severe obesity. Besides tradi-
tional procedures such as laparoscopic Roux-en-Y gastric by-
pass (RYGB), vertical sleeve gastrectomy (VSG) and adjust-
able gastric banding (LAGB), less invasive options are avail-
able such as the (transorally placed) duodenal-jejunal bypass
sleeve (DJBS). In general, these procedures lead to a loss of
body fat, a reduction of comorbidities and improvement of
long-term health risks. Remarkably, the mechanisms behind
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these outcomes are still poorly understood, and it is conceiv-
able that these comprise different combinations of biological
adaptations [1]. This is reflected in the markedly different
immediate effects on glycaemic control following different
procedures [2]. Recently, endoscopic gastroplication has be-
come available as a new minimal invasive technique. The
articulating circular endoscopic (ACE) stapler is used to re-
duce the volume of the stomach without removing tissue or
bypassing other intestinal regions. For this procedure, no skin
incisions are necessary; it is performed via a transoral route.
This procedure results in a median 34.9 % (IQR 17.8–46.6)
loss of excess weight in the first year. Moreover, only mild
adverse effects were reported so far [3]. Although several
studies have described metabolic and anti-inflammatory ef-
fects of bariatric surgery at a molecular level, studies on these
processes within the gastrointestinal (GI) tract are still limited.
This holds particularly true for the upper GI tract, as most
studies in this field have focussed on the mid or lower gastro-
intestinal tract [4–6]. Moreover, these studies concern effects
of RYGB, a procedure extensively changing GI anatomy and
physiology. The present study was undertaken to gain more
insight in the long-term effects and underlying mechanisms of
gastroplication in the upper GI tract: the stomach (fundus and
antrum) and the duodenum, and to relate these to general
health outcomes, including parameters of inflammation. To
this end, transcriptome and gene set enrichment analysis was




This study used biopsies and blood samples obtained from ten
patients who were part of the first human ACE stapler study
[3]. The Medical Ethical Committee of the Maastricht
Univers i ty Medica l Center+ in the Nether lands
(NCT02381340) approved the present study as a sub-study
aiming to further unravel underlying mechanisms. Before in-
clusion, written informed consent was obtained from each
participant. The inclusion criteria for the ACE stapler study
are described in detail by Paulus et al. [3]. In brief, participants
were 18 to 50 years old with a BMI of 40 to 45 kg/m2 or 30 to
39.9 kg/m2 in combination with one or more comorbidities
expected to improve with weight loss. The ACE stapler was
introduced into the stomach together with a thin endoscope.
By applying vacuum to the gastric tissue, a large full-thickness
(transmural) plication was drawn into the stapler head and
fixed with a staple ring. Reduction of the stomach volume
along the greater curvature was completed after creating a
maximum of eight plications in the fundus and two additional
plications in the antrum of the stomach. More details on the
procedure were published previously [3]. Mucosal biopsies
were taken from the fundus, antrum and duodenum with a
standard forceps before starting the procedure. Afterwards,
patients visited the outpatient clinic regularly and were stim-
ulated to adhere to a healthy lifestyle. A follow-up endoscopy
was planned 12 months after the procedure, at which the bi-
opsy procedure was repeated. Biopsies were snap frozen in
liquid nitrogen and stored at −80 °C until analysis. Table 1
shows a brief overview of the characteristics of included
patients.
RNA Isolation and Microarray Processing
RNA of the mucosal biopsies was isolated using TRIzol
reagent (Life technologies, Bleiswijk, Netherlands) and
further purified using the RNeasy micro kit (Qiagen,
Venlo, Netherlands). RNA yield was measured with the
Nanodrop ND-1000 Spectrophotometer, and the quality
of the RNA samples was verified with an Agilent 2100
Bio analyser (Agilent Technologies, Amstelveen,
Netherlands). One hundred nanogram of RNA was used
for whole transcript cDNA synthesis (Affymetrix, Inc.,
Santa Clara, USA). Hybridization, washing and scanning
of Affymetrix GeneChip Human Gene 1.1 ST arrays was
carried out according to standard Affymetrix protocols.
Microarray Analysis
For the analysis of the microarray results, each location
(i.e. fundus, antrum and duodenum) was analysed sepa-
rately. Arrays were normalized using the robust multi-
array average method [7, 8]. Probe sets were assigned to
unique gene identifiers, in this case Entrez IDs. The
probes on the arrays represent 19654 Entrez IDs [9].
Array data were analysed using MADMAX pipeline for
statistical analysis of microarray data [10]. Quality control
was performed, and all arrays met our criteria, except for
the fundus and antrum arrays from participant 5, which
were excluded. All data were filtered, and probe sets with
Table 1 Overview of characteristics of patients undergoing ACE
stapler procedure. Measurements were performed at baseline and 1 year
after the procedure. Ghrelin was measured after a 10 hour overnight fast
Baseline One year
Mean SEM Mean SEM
Age 39 2
Male/female ratio 6:4
BMI (kg/m2) 39.8 0.9 33.4 0.9
Excess weight loss (%) 37.9 4.8
Fasted active ghrelin level (pg/ml) 46.5 5.9 63.4 5.2
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expression values above 20 in at least 5 arrays were in-
cluded for further analysis. These data were used for gene
set enrichment analysis (GSEA; www.broadinstitute.
org/gsea [11]) in MADMAX. Gene sets with a false
discovery rate (FDR) <0.25 were considered significantly
enriched. The gene set enrichment analysis was visualized
using the enrichment plugin in Cytoscape with conserva-
tive filtering (p < 0.001 and FDR q < 0.05). For further
analysis of individual genes, a cut-off of IQR > 0.25 was
used to filter out genes that showed no variation between
the samples; Intensity-Based Moderated T-statistics
(IBMT) was used to assess significant differences with p
value <0.05.
Plasma Measurements
Blood samples were collected in EDTA-coated tubes, cen-
trifuged and stored at −80 C until analysis. The measure-
ment of plasma adiponectin and cytokine levels was per-
formed using an in-house developed and validated
Table 2 The effect of ACE
stapler treatment on fasted plasma
levels of inflammatory and
metabolic markers. Plasma levels
were measured before the
treatment (baseline) and 1 year
after
Plasma marker Baseline One year Treatment effect
Unit Mean SEM Mean SEM Difference p value
Adiponectin μg/ml 16.87 3.67 27.67 5.92 10.80 0.002*
HbA1c % 6.17 0.51 5.32 0.14 −0.85 0.004*
IL-1β pg/ml 1.42 0.06 1.37 0.08 −0.05 0.244
IL-6 pg/ml 10.90 1.83 7.41 1.80 −3.49 0.069
IL-7 pg/ml 11.52 1.24 10.43 2.01 −1.09 0.180
TNF-α pg/ml 2.14 0.10 2.00 0.14 −0.14 0.118
IFN-γ pg/ml 2.54 0.27 2.23 0.25 −0.32 0.099
MCP-1 pg/ml 60.70 7.33 46.68 7.74 −14.02 0.088
IL-8 pg/ml 7.03 1.03 6.55 1.44 −0.48 0.455
LAP/TGF-1 ng/ml 3.11 0.35 3.24 0.36 0.13 0.393
CRP mg/l 12.62 5.66 8.78 2.75 −3.85 0.248
Fig. 1 Expression of most highly significantly upregulated and
downregulated genes in fundus, antrum and duodenum, respectively.
Green is a signal log ratio of −2, and red is a signal log ratio of 2. Apart
from the mean fold change (FC) of the top regulated genes by the treat-
ment, signal log ratios are displayed to show inter-individual differences
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multiplex immunoassay (Laboratory of Translational
Immunology, University Medical Center Utrecht, the
Netherlands) based on Luminex technology (xMAP,
Luminex, Austin, USA). The assay was performed as de-
scribed previously [12]. Using heteroblock (Omega
Biologicals, Bozeman, USA), aspecific heterophilic im-
munoglobulins were preabsorbed. Acquisition was per-
formed with the Biorad FlexMAP3D (Biorad laboratories,
Hercules, USA) in combination with xPONENT software
version 4.2 (Luminex, Austin, USA). Data was analysed
by 5-parametric curve fitting using Bio-Plex Manager
software, version 6.1.1 (Biorad laboratories, Hercules,
USA). HbA1c levels were determined routinely at the
Department of Clinical Chemistry of the Maastricht
University Medical Center. Active ghrelin was measured
using an established in-house radioimmunoassay
(Millipore, Massachusetts, USA).
Statistical Analysis
Statistical analyses were performed using Prism 5.0
(GraphPad Software, Inc. La Jolla, USA). The effects of
treatment on plasma levels of inflammatory markers and
adiponectin were tested by paired t tests for normally
Fig. 2 Gene set enrichment analysis of the fundus, antrum and
duodenum. Each node indicates a conservative filtered gene set
(p < 0.001 and FDR q < 0.05), and the connecting lines indicate
overlapping genes between the nodes/gene sets. Red is enriched; blue is
depleted gene sets
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distributed variables and Wilcoxon’s signed rank tests for
non-normally distributed variables. Spearman’s rank cor-
relation coefficient analysis was performed to investigate
the association between changes in biochemical parame-
ters with changes in mRNA expression (signal log ratio).
A p value <0.05 was considered statistically significant.
Data are presented as mean with standard error of the
mean (SEM). Statistical analysis of transcriptome data
was described above.
Results
Effects of Gastroplication on Systemic Metabolic
and Inflammatory Parameters One Year After
Intervention
Plasma levels of glycated haemoglobin, adiponectin and
several pro-inflammatory mediators before and after inter-
vention are shown in Table 2. Significant changes were
found for adiponectin and HbA1c. Adiponectin showed a
1.64-fold increase (p = 0.002) in the patients who
underwent ACE stapler treatment. Glycated haemoglobin
(HbA1c) was significantly decreased (p = 0.004) by the
treatment. Plasma IL-6 showed a tendency to decrease
following ACE stapler treatment by a factor 1.47. MCP-
1 levels also showed a decrease (1.3-fold), but this effect
did not reach statistical significance.
Effects on Tissue Gene Expression Mainly Relate
to Inflammatory Pathways
Gene expression changes 1 year after intervention com-
pared to baseline were analysed for different locations of
the upper gastrointestinal tract, namely fundus, antrum
and duodenum. After intervention, 727 genes (259 upreg-
ulated, 468 downregulated) were significantly changed in
the fundus, 1846 (951 upregulated, 895 downregulated) in
the antrum and 921 genes (480 upregulated, 441 down-
regulated) in the duodenum. The top 20 upregulated and
downregulated genes in all three locations are shown in
Fig. 1. In both fundus and duodenum, a considerable
number of downregulated genes have been associated
with immunity and inflammatory pathways. In the fundus,
the expression of immune-related genes like IGHV3-33,
C7, CCL21, IFI6, IFI27, C1QB was downregulated, and
CCL18, CLC, CXCR4, IGHV1-24, RSG1, IGLV3-10,
IGHV3-33, IGLV7-46 were downregulated in the duode-
num. In the antrum, there was an upregulation of some
neuroendocrine-associated genes, namely PAX6, CHGB,
SCG5.
Gene Set Enrichment Analysis Reveals Potential Processes
Involved
To gain more insight into the processes changed 1 year
following the stomach volume reduction procedure, gene
Fig. 3 Changes in gene
expression of ghrelin and
MBOAT4 and their correlation to
plasma ghrelin. a The graphs
show RMA normalized
intensities of microarray data at
baseline and 1 year after
gastroplication in biopsies of
fundus, antrum and duodenum.
Fold changes are indicated on top
of the bars, significant changes
are marked with asterisk
(p < 0.05). All graphs show mean
and SEM. b Correlation between
signal log ratios of ghrelin
(GHRL) and MBOAT4 in the
fundus with changes in plasma
active ghrelin levels measured in
a fasted state before and 1 year
after the procedure
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set enrichment analysis (GSEA) was performed. This
computational method uses molecular signatures to asso-
ciate changes in gene expression with known biological
processes. Analysis resulted in 236 (2 upregulated, 234
downregulated) enriched gene sets for fundus, 546 (474
upregulated, 72 downregulated) enriched gene sets for
antrum and 253 (182 upregulated, 71 downregulated)
enriched gene sets for duodenum. In the antrum, more
gene sets were upregulated, whereas in the fundus, most
gene sets were downregulated (Fig. 2). Of these downreg-
ulated gene sets in the fundus, many were related to im-
mune responses, mostly to the complement system, pre-
sentation and recognition of antigens (self or pathogenic)
and T cell receptor signalling. Also in the duodenum,
some of the downregulated gene sets were related to the
innate immunity. In the antrum, cell cycle related gene
sets were strongly enriched. In the duodenum, the enrich-
ment analysis showed also a slight upregulation of cell
cycle processes. Here, more metabolic pathways were ap-
parently upregulated, including those associated with ‘fat
digestion and absorption’ and ‘metabolism of lipids and
lipoproteins’. All gene sets are specified in Table S1.
Changes in Gastrointestinal Hormone Expression
Being one of the main gastric hormones, ghrelin is not
only involved in appetite regulation but also in immunity
[13]. Two genes related to ghrelin were significantly
changed in specific locations of the GI tract (Fig. 3a). In
the fundus, there was a downregulation of MBOAT4
(FC = −1.49), the gene encoding the ghrelin-activating
enzyme GOAT4. Furthermore, there was a trend for
downregulation of ghrelin (GHRL) expression itself in
the fundus (FC = −1.88, p = 0.19) and antrum
(FC = −3.13, p = 0.11) and a significant downregulation
in the duodenum (FC = −1.34).
In the fundus, the ghrelin gene expression (GHRL) was
positively correlated to fasted plasma changes of active ghrel-
in (Spearman correlation coefficient = 0.826, p = 0.015), and
for MBOAT4 expression, there was a tendency for correlation
(Spearman correlation coefficient = 0.69, p = 0.069) (Fig. 3b).
Although the correlation between changes in ghrelin and
GHRL expression seems to be influenced by a single patient,
excluding this patient still resulted in a significant correlation.
Conclusions
Results of the present study add important physiological back-
ground information to the clinical outcomes observed in pa-
tients after undergoing ACE stapler gastroplication. Our plas-
ma analyses revealed beneficial effects on HbA1c and
adiponectin levels 1 year after surgery, indicating an
improvement of glycaemic control and a favourable shift in
adipose tissue mass and/or inflammatory status, respectively.
This rise in plasma adiponectin and reduction of HbA1c is in
line with previous studies in which a loss of excess body fat
was achieved, including those involving other surgical and
non-surgical weight loss interventions [14–17].We also found
tendencies for reduced plasma IL-6 and MCP-1 levels, 1 year
after intervention. Reduced levels of inflammatory markers
are generally assumed to result from a reduction of visceral
fat mass in particular, which plays a major role in the low
grade inflammatory state associated with obesity [18]. The
total number of patients in our study population is quite small,
and it is conceivable that statistical significance might have
been reached with a larger patient group. Several other studies
have found significant reductions in inflammatory markers
like CRP, MCP-1 and IL-6 after bariatric surgery, while others
did not find such an effect [19–21].
To our knowledge, this study is the first to analyse long-
term whole transcriptome changes in the upper gastrointesti-
nal tract after a new transoral bariatric procedure.
Gastroplication reduces gastric volume without altering intes-
tinal anatomy, as is the case with RYGB. In contrast to bypass
surgery, exposure of the intestinal epithelium to nutrients and
their metabolites is largely maintained after this endoscopic
gastroplication. At the same time, small changes related to
different GI transit characteristics or changes in the
microbiome might still occur.
Analysis of the large amount of data using unbiased tran-
scriptome analysis clearly pointed towards a reduction in in-
flammatory tone in the fundus and duodenum tissues as man-
ifested by the downregulation of a wide variety of
inflammation-related gene sets. The downregulated gene sets
in the fundus were mostly related to innate immunity, and
particularly associated with downregulation of the comple-
ment system, presentation and recognition of antigens (self
or pathogenic), IFN-γ signalling and T cell receptor signal-
ling. In the duodenum, the main downregulated gene set was
associated with the complement system. Moreover, the top 20
highly changed genes in these locations also suggest notable
downregulation of many immune-related processes, of which
several were related to chemokines, complement system, in-
terferon signalling and immunoglobulins. These results coin-
cided with the weight loss, improvement of HbA1c levels and
decrease of whole-body inflammatory tone in these patients.
Based on the present study, we cannot establish whether the
apparent reduction of inflammatory tone in the upper GI tract
has a predominantly local cause, i.e. due to a changed food-
intake pattern or digestion process, or whether it is related to a
reduction of low-grade systemic inflammation due to the re-
duction of body fat mass.
Increasing evidence points to a link between intestinal in-
flammation status in general, obesity and (or) diabetes. In
obesity, increased innate cell densities, among which
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macrophages, natural killer cells and T cells, especially the
proportion of cytotoxic CD8 T cells, have been observed in
the jejunal epithelium. These epithelial T cells were found to
be associated with local and systemic comorbidities.
Furthermore, isolated T cells from obese patients decreased
insulin sensitivity of epithelial cells in vitro [22]. Another
study reported that diet-induced weight loss resulted in a
downregulation of inflammatory pathways and inflammatory
cytokines IL-8, TNF-α, MCP-1 and IL-1β, in recto-sigmoid
mucosal tissue [23]. Moreover, increased intestinal inflamma-
tory gene expression of TNF-α, IL-6, ICAM and PTGS-2 was
found in insulin-resistant obese patients compared to non-
insulin-resistant obese patients, suggesting that intestinal in-
flammation is involved in diabetes during obesity [24, 25]. A
prominent feature of the immune system in the gastrointestinal
tract is to provide adequate protection without stimulating
excessive inflammation, thereby maintaining a fine balance
[26, 27]. A pro-inflammatory immune status of the gastroin-
testinal tract in obese patients might be protective against in-
creased luminal challenges associated within obesity but de-
teriorating for insulin resistance [22]. Furthermore, this pro-
inflammatory status might be linked to the increased preva-
lence of inflammatory bowel disease and cancer in obese pa-
tients [28–30]. In summary, we can only speculate whether the
reduced inflammatory microenvironment in gastric and duo-
denal tissue found after gastroplication can be considered as a
positive or negative outcome.
In the antral tissue, gene sets related to cell cycle pro-
cesses and extracellular matrix were increased. This might
be explained by dilation of the stomach, a common ob-
servation after gastric volume reduction [31–34]. While
gastric volume was not quantified, we perceived the stom-
ach as larger at 1-year follow-up than immediately after
gastroplication.
An interesting observation was that the mean gene ex-
pression of ghrelin and the enzyme GOAT, responsible for
ghrelin acylation, decreased after gastroplication in some
of the tissues. At the same time, plasma fasted active
ghrelin was increased, and there was a positive correlation
between the gene expression of ghrelin and plasma values
of active ghrelin. Ghrelin is one of the most prominent
hormones secreted from the upper gastrointestinal tract
and does not only play a role in appetite regulation but
also in inflammation [13]. Consistent with our results, in
RYGB patients, significant lower levels of jejunal ghrelin
gene expression have been reported after 10 months [6].
Furthermore, GOAT mRNA expression and GOAT-
positive cell numbers were lower in a non-obese group
compared to morbidly obese patients, although no chang-
es in jejunal ghrelin expression were detected [35].
Moreover, more ghrelin positive cells were found in the
stomach of morbidly obese and overweight patients com-
pared to healthy normal weight controls [36, 37], which
might indicate that with weight loss, the number of
ghrelin-releasing cells will decrease. The discrepancy with
ghrelin expression in the gastrointestinal tract and plasma
ghrelin values might be explained by a reduced secretory
activity of (a higher number of) ghrelin producing cells in
obesity, as suggested by Widmayer et al. [36]. However,
within our patients, there was a positive correlation be-
tween its gene expression and plasma levels, indicating
that upregulated expression of ghrelin in the fundus was
associated with greater increase in fasted ghrelin levels
and downregulated expression with a smaller increase
1 year after gastroplication. The underlying cause of the
observed changes cannot be pinpointed in our study. It is
possible that the changes in ghrelin are dependent on the
surgical procedure, which takes place at the main site of
ghrelin secretion. Furthermore, the implications of these
changes in ghrelin are not fully understood and need fur-
ther investigation to crystallize the underlying mechanism
and to explore the potential of these changes in obesity
treatment.
There are some strengths and limitations to this study.
The within-person measurement of changes in gastrointes-
tinal gene expression is unique as most studies in this
field are observational. By applying a prospective design,
we were able to perform paired analysis and look specif-
ically for changes induced by the gastroplication treat-
ment instead of comparing obese subjects with lean con-
trols. Whole transcriptome analysis enabled us to investi-
gate changes in an unbiased manner. One of the limita-
tions of this study is that it was not powered to find
differences in inflammatory markers. Therefore, the inclu-
sion of more patients could have strengthened the study.
Furthermore, a control group on a lifestyle intervention
program could help differentiate between weight loss ef-
fects and strictly procedural effects.
This study presents the long-term effects of a new
transoral gastroplication treatment in morbidly obese pa-
tients. We show that this recently developed ACE stapler
procedure was not only effective in reducing body weight
as presented before [3], but also improved glycated
haemoglobin levels and increased plasma adiponectin.
Furthermore, whole transcriptome analysis suggested a
marked downregulation of inflammatory gene sets in both
the fundus and duodenum, coinciding with changes in
plasma cytokines. Moreover, gene expression of ghrelin
and its activating enzyme GOAT were reduced after
gastroplication. The apparent reduction of inflammatory
tone in the upper GI tract may be a consequence of an
improved metabolic health status as associated with
weight loss, or alternatively caused by the procedure
itself.
In conclusion, this new transoral gastroplication treat-
ment which induced significant weight loss and
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improved plasma levels of adiponectin and glycated
haemoglobin coincides with a reduced inflammatory tone
in the upper GI tract. The clinical relevance of our find-
ings remains to be established, as there is still limited
knowledge on the role of inflammatory pathways in the
upper GI tract in obesity.
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